News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
794,660 Results
Type
Article (59889)
Company Profile (680)
Press Release (734074)
Multimedia
Podcasts (143)
Webinars (22)
Section
Business (219306)
Career Advice (2858)
Deals (38070)
Drug Delivery (145)
Drug Development (87031)
Employer Resources (188)
FDA (18028)
Job Trends (16372)
News (374414)
Policy (37596)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2949)
Academic (1)
Accelerated approval (39)
Adcomms (32)
Allergies (160)
Alliances (54144)
ALS (189)
Alzheimer's disease (1794)
Antibody-drug conjugate (ADC) (365)
Approvals (18255)
Artificial intelligence (626)
Autoimmune disease (185)
Automation (45)
Bankruptcy (390)
Best Places to Work (12425)
BIOSECURE Act (23)
Biosimilars (211)
Biotechnology (428)
Bladder cancer (174)
Brain cancer (68)
Breast cancer (684)
Cancer (5237)
Cardiovascular disease (462)
Career advice (2428)
Career pathing (43)
CAR-T (309)
CDC (65)
Celiac Disease (2)
Cell therapy (827)
Cervical cancer (40)
Clinical research (74034)
Collaboration (1907)
Company closure (4)
Compensation (1231)
Complete response letters (77)
COVID-19 (2987)
CRISPR (106)
C-suite (944)
Cystic fibrosis (151)
Data (6622)
Decentralized trials (2)
Denatured (42)
Depression (156)
Diabetes (543)
Diagnostics (7207)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (295)
Drug pricing (226)
Drug shortages (35)
Duchenne muscular dystrophy (254)
Earnings (94844)
Editorial (67)
Employer branding (21)
Employer resources (163)
Events (126446)
Executive appointments (1051)
FDA (21374)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1608)
Gene editing (224)
Generative AI (56)
Gene therapy (688)
GLP-1 (1117)
Government (5288)
Grass and pollen (7)
Guidances (388)
Healthcare (20458)
HIV (71)
Huntington's disease (53)
IgA nephropathy (90)
Immunology and inflammation (289)
Immuno-oncology (71)
Indications (133)
Infectious disease (3301)
Inflammatory bowel disease (215)
Inflation Reduction Act (15)
Influenza (132)
Intellectual property (268)
Interviews (506)
IPO (17480)
IRA (59)
Job creations (4338)
Job search strategy (2002)
JPM (69)
Kidney cancer (19)
Labor market (92)
Layoffs (626)
Leadership (44)
Legal (9358)
Liver cancer (100)
Longevity (18)
Lung cancer (702)
Lymphoma (393)
Machine learning (47)
Management (64)
Manufacturing (898)
MASH (178)
Medical device (14802)
Medtech (14867)
Mergers & acquisitions (21699)
Metabolic disorders (1424)
mRNA (192)
Multiple sclerosis (174)
NASH (18)
Neurodegenerative disease (363)
Neuropsychiatric disorders (103)
Neuroscience (3178)
Neurotech (1)
NextGen: Class of 2026 (7369)
Non-profit (4999)
Now hiring (69)
Obesity (684)
Opinion (332)
Ovarian cancer (174)
Pain (228)
Pancreatic cancer (245)
Parkinson's disease (310)
Partnered (34)
Patents (542)
Patient recruitment (546)
Peanut (64)
People (63135)
Pharmaceutical (127)
Pharmacy benefit managers (34)
Phase 1 (22975)
Phase 2 (32332)
Phase 3 (24325)
Pipeline (6027)
Policy (342)
Postmarket research (3037)
Preclinical (9896)
Press Release (71)
Prostate cancer (270)
Psychedelics (55)
Radiopharmaceuticals (313)
Rare diseases (983)
Real estate (6690)
Recruiting (75)
Regulatory (27879)
Reports (59)
Research institute (2682)
Resumes & cover letters (467)
Rett syndrome (31)
RNA editing (18)
RSV (90)
Schizophrenia (163)
Series A (265)
Series B (204)
Service/supplier (25)
Sickle cell disease (108)
Special edition (29)
Spinal muscular atrophy (173)
Sponsored (46)
Startups (4022)
State (2)
Stomach cancer (21)
Supply chain (114)
Tariffs (99)
The Weekly (99)
Vaccines (1165)
Venture capital (98)
Weight loss (464)
Women's health (100)
Worklife (22)
Date
Today (189)
Last 7 days (933)
Last 30 days (3040)
Last 365 days (31886)
2026 (5401)
2025 (32273)
2024 (37459)
2023 (42037)
2022 (53394)
2021 (58163)
2020 (57041)
2019 (50261)
2018 (38241)
2017 (35325)
2016 (35344)
2015 (41223)
2014 (35184)
2013 (30569)
2012 (32685)
2011 (33291)
2010 (31424)
Location
Africa (996)
Alabama (92)
Alaska (7)
Arizona (337)
Arkansas (15)
Asia (46101)
Australia (7708)
California (12059)
Canada (3425)
China (1212)
Colorado (508)
Connecticut (525)
Delaware (357)
Europe (102230)
Florida (1801)
Georgia (391)
Hawaii (4)
Idaho (64)
Illinois (967)
India (77)
Indiana (560)
Iowa (24)
Japan (465)
Kansas (133)
Kentucky (46)
Louisiana (33)
Maine (72)
Maryland (1505)
Massachusetts (8792)
Michigan (353)
Minnesota (668)
Mississippi (7)
Missouri (143)
Montana (36)
Nebraska (29)
Nevada (134)
New Hampshire (86)
New Jersey (3225)
New Mexico (32)
New York (3177)
North Carolina (1626)
North Dakota (10)
Northern California (5854)
Ohio (361)
Oklahoma (23)
Oregon (52)
Pennsylvania (2407)
Puerto Rico (24)
Rhode Island (52)
South America (1377)
South Carolina (70)
South Dakota (1)
Southern California (4679)
Tennessee (187)
Texas (1882)
United States (43133)
Utah (362)
Vermont (1)
Virginia (299)
Washington D.C. (87)
Washington State (987)
West Virginia (4)
Wisconsin (136)
Wyoming (2)
794,660 Results for "idorsia pharmaceuticals us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
January 28, 2026
·
6 min read
Press Releases
Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
January 5, 2026
·
8 min read
Press Releases
Idorsia’s daridorexant in women during menopausal transition age with insomnia
January 6, 2026
·
12 min read
Press Releases
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
January 12, 2026
·
11 min read
Press Releases
Invitation to Idorsia’s FY 2025 Financial Reporting webcast and conference call
February 12, 2026
·
1 min read
Press Releases
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
January 12, 2026
·
4 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
·
9 min read
Press Releases
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
February 26, 2026
·
10 min read
Press Releases
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
November 10, 2025
·
17 min read
Press Releases
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
September 22, 2025
·
6 min read
1 of 79,466
Next
